Ionis Pharmaceuticals Inc
IONS
Market Cap$5.76B
Close$
$-20.32
152% downside
Current Fair Value
152% downsideOvervalued by 152% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.76 Billion |
|---|---|
| Enterprise Value | $4.83 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.67 |
| Beta | 0.5 |
| Outstanding Shares | 145,965,374 |
| Avg 30 Day Volume | 952,355 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.97 |
|---|---|
| PEG | -100.73 |
| Price to Sales | 7.82 |
| Price to Book Ratio | 19.54 |
| Enterprise Value to Revenue | 6.22 |
| Enterprise Value to EBIT | -12.41 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 4.3 |
Revenue Sources
No data
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...